Methodological Evaluation of the SEA-AD MTG Differential Expression Dataset
The SEA-AD differential expression analysis comparing Alzheimer's disease to controls in the middle temporal gyrus represents a significant resource for understanding AD pathophysiology at cellular resolution, yet the methodology carries.
The SEA-AD differential expression analysis comparing Alzheimer's disease to controls in the middle temporal gyrus represents a significant resource for understanding AD pathophysiology at cellular resolution, yet the methodology carries inherent limitations that warrant careful interpretation. The primary strength of this dataset lies in its single-nucleus resolution, which enables cell-type-specific differential expression analysis—a critical advancement over bulk RNA-seq approaches that obscure cellular heterogeneity. However, the translation of cell-level findings to biological conclusions remains methodologically fraught, particularly when comparing across individuals with fundamentally different cellular compositions due to disease-related cell loss. A central methodological concern involves the statistical framework for handling biological versus technical variation. Single-cell data presents a unique challenge: while thousands of cells are measured per individual, the true biological replicate is the donor. Treating individual cells as independent observations inflates statistical power and produces spurious findings driven by population structure.
...
The SEA-AD differential expression analysis comparing Alzheimer's disease to controls in the middle temporal gyrus represents a significant resource for understanding AD pathophysiology at cellular resolution, yet the methodology carries inherent limitations that warrant careful interpretation. The primary strength of this dataset lies in its single-nucleus resolution, which enables cell-type-specific differential expression analysis—a critical advancement over bulk RNA-seq approaches that obscure cellular heterogeneity. However, the translation of cell-level findings to biological conclusions remains methodologically fraught, particularly when comparing across individuals with fundamentally different cellular compositions due to disease-related cell loss. A central methodological concern involves the statistical framework for handling biological versus technical variation. Single-cell data presents a unique challenge: while thousands of cells are measured per individual, the true biological replicate is the donor. Treating individual cells as independent observations inflates statistical power and produces spurious findings driven by population structure. Pseudobulk approaches, which aggregate counts within cell types per individual before testing, represent the current best practice (Squair et al., 2021; PMID), yet the field lacks consensus on optimal implementation. The SEA-AD methodology likely employs pseudobulk aggregation for primary analyses, but transparency regarding the specific approach—including how zero-inflated counts are handled and whether donor-level covariates are appropriately modeled—is essential for reproducibility. Furthermore, the MTG region's specificity raises important questions about generalizability. The middle temporal gyrus is particularly vulnerable to AD pathology, showing early tau accumulation and metabolic dysfunction, but this specialization may not reflect patterns observed in more affected regions such as the entorhinal cortex or superior frontal gyrus. The field has documented substantial regional variation in AD transcriptomic signatures (PMID:38913039), suggesting that findings from MTG may not translate directly to other brain regions or to the broader AD population. ## Caveats and Limitations Several confounding factors require acknowledgment. First, post-mortem brain tissue introduces substantial technical variation: RNA integrity number (RIN), post-mortem interval (PMI), and agonal state can all drive gene exp
Debate provenance: derived from debate `sess_gap-methodol-20260427-041425-f1540b8d` on question: Methodology challenge: dataset 'SEA-AD Differential Expression: AD vs Control (MTG)' — evaluate design, statistical methods, and reproducibility.. Consensus signal: domain_expert, skeptic, theorist discussed the mechanism terms Alzheimer, Contribution, Dataset, Differential, Evaluation, Expression, MTG, Methodological. Novelty signal: skeptic-discussed-counterarguments.
🧬 Mechanism
No curated mechanism pathway recorded for this hypothesis.
⚖️ Evidence
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — SEA
No curated PDB or AlphaFold mapping for SEA yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.